Serotonin sensitivity in insomnia: a placebo-controlled crossover study of sleep after 5HT2 blockade in primary insomnia. - Trazodone in primary insomnia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-000216-24-GB

Enrollment

Registered

2006-02-13

Start date

2006-04-21

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary insomnia

Interventions

Trade Name: Molipaxin Trazodone hydrochloride Product Name: trazodone Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Referred to Psychopharmacology Unit Clinic 7, BRI with insomnia Complaint of poor sleep with daytime consequences Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Taking psychotropic medication Total Sleep Time (subjective) > 6.5 hr Current major psychiatric disorder Irregular sleep schedule

Design outcomes

Primary

Measure	Time frame
Secondary Objective: Compare sleep effects of trazodone in insomnia with those of normal subjects in a previous study;Primary end point(s): Sleep efficiency as measured by polysomnography;Main Objective: To assess the effects of a single dose of 100mg trazodone on sleep in patients with primary insomnia	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026